118 related articles for article (PubMed ID: 38864578)
21. Initial antiretroviral therapy regimen and risk of heart failure.
Silverberg MJ; Pimentel N; Leyden WA; Leong TK; Reynolds K; Ambrosy AP; Towner WJ; Hechter RC; Horberg M; Vupputuri S; Harrison TN; Lea AN; Sung SH; Go AS; Neugebauer R
AIDS; 2024 Mar; 38(4):547-556. PubMed ID: 37967231
[TBL] [Abstract][Full Text] [Related]
22. CD4/CD8 Ratio Recovery Among People Living With HIV Starting With First-Line Integrase Strand Transfer Inhibitors: A Prospective Regional Cohort Analysis.
Han WM; Avihingsanon A; Rajasuriar R; Tanuma J; Mundhe S; Lee MP; Choi JY; Pujari S; Chan YJ; Somia A; Zhang F; Kumarasamy N; Tek Ng O; Gani Y; Chaiwarith R; Pham TN; Do CD; Ditangco R; Kiertiburanakul S; Khol V; Ross J; Jiamsakul A;
J Acquir Immune Defic Syndr; 2023 Feb; 92(2):180-188. PubMed ID: 36625858
[TBL] [Abstract][Full Text] [Related]
23. Integrase Strand Transfer Inhibitors Are Associated With Incident Diabetes Mellitus in People With Human Immunodeficiency Virus.
O'Halloran JA; Sahrmann J; Parra-Rodriguez L; Vo DT; Butler AM; Olsen MA; Powderly WG
Clin Infect Dis; 2022 Dec; 75(12):2060-2065. PubMed ID: 35521785
[TBL] [Abstract][Full Text] [Related]
24. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents.
The RESPOND Study Group
AIDS; 2021 May; 35(6):869-882. PubMed ID: 33443370
[TBL] [Abstract][Full Text] [Related]
25. Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus.
Asundi A; Olson A; Jiang W; Varshney SP; White LF; Sagar M; Lin NH
AIDS Res Hum Retroviruses; 2022 Mar; 38(3):208-215. PubMed ID: 34877881
[TBL] [Abstract][Full Text] [Related]
26. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
27. Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
Masiá M; Padilla S; Barber X; Sanchis M; Terol G; Lidón F; Gutiérrez F
Medicine (Baltimore); 2016 Mar; 95(11):e3108. PubMed ID: 26986155
[TBL] [Abstract][Full Text] [Related]
28. Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV.
O'Halloran JA; Wang K; Spence AB; Williams DW; Dastgheyb R; Fitzgerald KC; Kamkwalala AR; Maki PM; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Lahiri CD; Sheth AN; Xu Y; Rubin LH
J Acquir Immune Defic Syndr; 2021 Apr; 86(5):593-599. PubMed ID: 33394812
[TBL] [Abstract][Full Text] [Related]
29. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus.
Chow W; Donga P; Côté-Sergent A; Rossi C; Lefebvre P; Lafeuille MH; Emond B; Hardy H
Curr Med Res Opin; 2020 Aug; 36(8):1313-1323. PubMed ID: 32459155
[TBL] [Abstract][Full Text] [Related]
30. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
[TBL] [Abstract][Full Text] [Related]
31. Incidence of Hyperlipidemia among Adults Initiating Antiretroviral Therapy in the HIV Outpatient Study (HOPS), USA, 2007-2021.
Li J; Agbobli-Nuwoaty S; Palella FJ; Novak RM; Tedaldi E; Mayer C; Mahnken JD; Hou Q; Carlson K; Thompson-Paul AM; Durham MD; Buchacz K
AIDS Res Treat; 2023; 2023():4423132. PubMed ID: 38078054
[TBL] [Abstract][Full Text] [Related]
32. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
33. First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines.
El Bouzidi K; Jose S; Phillips AN; Pozniak A; Ustianowski A; Gompels M; Winston A; Schaap A; Dunn DT; Sabin CA;
AIDS; 2020 Oct; 34(12):1823-1831. PubMed ID: 32516283
[TBL] [Abstract][Full Text] [Related]
34. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.
Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A
J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527
[TBL] [Abstract][Full Text] [Related]
35. Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors.
Donga P; Emond B; Shah A; Bookhart BK; Anderson D; Vermette-Laforme M; Rossi C; Lafeuille MH
J Comp Eff Res; 2023 Jan; 12(1):e220147. PubMed ID: 36445208
[No Abstract] [Full Text] [Related]
36. Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV.
Erlandson KM; Mohaweche R; Morrow M; Mawhinney S; Khuu V; Boyd M; Balasubramanyam A; Melanson EL; Lake JE
J Antimicrob Chemother; 2024 Jan; 79(1):179-185. PubMed ID: 38000089
[TBL] [Abstract][Full Text] [Related]
37. Metabolic Changes Associated With the Use of Integrase Strand Transfer Inhibitors Among Virally Controlled Women.
Summers NA; Lahiri CD; Angert CD; Aldredge A; Mehta CC; Ofotokun I; Kerchberger AM; Gustafson D; Weiser SD; Kassaye S; Konkle-Parker D; Sharma A; Adimora AA; Bolivar H; Cocohoba J; French AL; Golub ET; Sheth AN
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):355-362. PubMed ID: 33060420
[TBL] [Abstract][Full Text] [Related]
38. Reduction of CD8 T Cell Functionality but Not Inhibitory Capacity by Integrase Inhibitors.
Richter E; Bornemann L; Korencak M; Alter G; Schuster M; Esser S; Boesecke C; Rockstroh J; Gunzer M; Streeck H
J Virol; 2022 Mar; 96(5):e0173021. PubMed ID: 35019724
[TBL] [Abstract][Full Text] [Related]
39. No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain.
Verburgh ML; Wit FWNM; Boyd A; Reiss P; Van der Valk M;
AIDS; 2023 Oct; 37(12):1843-1850. PubMed ID: 37433218
[TBL] [Abstract][Full Text] [Related]
40. Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents: A 10-Year Observational Study.
Taramasso L; Di Biagio A; Bovis F; Forlanini F; Albani E; Papaioannu R; Giacomet V
Microorganisms; 2020 Jun; 8(6):. PubMed ID: 32521616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
